Theriva Biologics Announced Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
Portfolio Pulse from Charles Gross
Theriva Biologics (NYSE:TOVX) announced progress in VIRAGE, a Phase 2b clinical trial evaluating VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma. Patient dosing has begun in the U.S. and Spain, with the trial expected to be fully-enrolled by Q1 2024. The treatment has been well tolerated with a consistent safety profile.
August 04, 2023 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics' ongoing Phase 2b trial of VCN-01 is progressing well, with patient dosing initiated in the U.S. and Spain. The trial is expected to be fully-enrolled by Q1 2024.
The news of progress in Theriva's Phase 2b trial is positive for the company. The initiation of patient dosing in the U.S. and Spain indicates that the trial is progressing as planned. If the trial continues to go well and the drug proves to be effective, it could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100